Nabriva Therapeutics and Vizient Join Hands to Offer XENLETA

Nabriva Therapeutics plc and Vizient together have agreed to offer XENLETA to treat community-acquired bacterial pneumonia (CABP).

FREMONT, CA: Nabriva Therapeutics plc and Vizient join hands to offer XENLETA, a treatment for community-acquired bacterial pneumonia (CABP), as a contracted product through Vizient's Pharmacy Network Program. To enhance patient outcomes and minimize costs, Vizient offers knowledge, analytics, and advisory services, as well as a contract portfolio totaling more than $110 billion in annual purchasing volume.

Nabriva CEO Ted Schroeder commented, “We are excited by Vizients decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals. Based on data from the Healthcare Cost and Utilization Project, it is estimated approximately 3 million adults are diagnosed with CABP in the hospital setting annually. Importantly, many of these patients may be at increased risk for adverse effects associated with respiratory fluoroquinolone or reside in areas with a high (>25%) prevalence of macrolide resistance. 

We are enthusiastic about the opportunity to provide clinicians a short-course, IV and oral monotherapy treatment option that addresses these unmet medical needs for their CABP patients.”

Nabriva Therapeutics is a biopharmaceutical business focused on researching and marketing novel anti-infective drugs for the treatment of serious illnesses. Nabriva Therapeutics was awarded a U.S. patent. XENLETA®, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia, has received FDA approval (CABP). CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complex urinary tract infections (cUTI), including acute pyelonephritis, is also being developed by Nabriva Therapeutics. Merck & Co. subsidiaries have an exclusive arrangement with Nabriva. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO®.